Aurinia Pharmaceuticals AUPH Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's accrued expenses?
- Aurinia Pharmaceuticals (AUPH) reported accrued expenses of $8.62M in Q1 2026.
- How has Aurinia Pharmaceuticals's accrued expenses changed year-over-year?
- Aurinia Pharmaceuticals's accrued expenses increased by 40.0% year-over-year, from $6.16M to $8.62M.
- What is the long-term trend for Aurinia Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's accrued expenses has grown at a 24.1% compound annual growth rate (CAGR), from $6.41M to $18.87M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.